Define clinical exposure associated with QTc liability

Data Card

Define clinical exposure associated with QTc liabilityEarly cardiac derisking: A clinically translatable hiPSC cardiomyocyte assay

Achieve action potential recordings from intrinsically paced hiPSC-CMs with Metrion’s clinically predictive hiPSC cardiomyocyte assay.

  • Simultaneous high-resolution measurement across 96 well plate at 10,000 Hz
  • Recordings using voltage-sensitive dye equivalent in quality to patch clamp
  • Multiple endpoints evaluated (APD20/50/90, rise time, beat rate, triangulation)
  • Measurement of acute (30min) and chronic (24h/48h) effects
  • Predicts clinical exposure associated with 10ms QTc prolongation
  • Defines exposure associated with QRS probability
  • Highlights unknown acute/chronic toxicity

Read more about our hiPSC cardiomyocyte assay.

Contact us for a quote or discussion



Recommended Publications
Latest Publications
Application of a High-Throughput Human Stem Cell Cardiomyocyte Assay for Predicting Drug-Induced Changes in ECG Parameters During Drug Discovery and Development

Understanding cardiac safety early is critical in drug development. In their latest poster, Jazz Pharmaceuticals, explain how they utilised Metrion’s clinically translatable cardiotoxicity assay to do exactly that.

Early In Vitro Preclinical Cardiovascular Safety Assessment for Smarter Drug Discovery

Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.

View All
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram